Although the bivalent COVID-19 vaccine conferred moderate protection against symptomatic disease, hybrid immunity provided the strongest protection.

The Phase 1 trial is an open label, dose ranging clinical study designed to evaluate Vaxart’s second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.

"Bivalent mRNA booster vaccination in adults aged 65 years or older is an effective and essential tool to reduce their risk of hospitalisation and death due to Covid-19.

Moderna has reported preliminary clinical results with a bivalent version of its COVID-19 vaccine that combines its original version with another targeting the Beta variant, and seems to offer ...

The temporary monovalent and bivalent booster side effects of vaccination—including chills, fever, headache, pain at the ...

The “bivalent vaccine” will be made available to people who have received two doses of existing vaccines, starting with elderly people and those with underlying health conditions, according to ...

Regulatory authorities in the US are investigating a possible link between the new Pfizer/BioNTech bivalent COVID-19 booster vaccine and strokes in people aged 65 or over, but still recommend the ...